BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ixabepilone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ixabepilone\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT00877500-2144@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ixabepilone: Phase 2 readout est. (NCT00877500)
DESCRIPTION:Ixabepilone\, phase 2\, Breast Cancer.\nStudy: Ixabepilone in T
 reating Participants With Significant Residual Disease of HER2/Neu Negativ
 e Invasive Breast Cancer After Systemic Therapy\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ixabepilone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT00877500
URL:https://assetmemo.bio/drug/ixabepilone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
